Protective immunity of pneumococcal glycoconjugates

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Pneumococcal polysaccharides (PSs), T-cell independent type 2 (TI-2) antigens, elicit weak immune responses in young children.
• Splenic marginal zone B cells are crucial for TI-2 antibody responses and defense against bacterial pathogens.

Purpose of the Study:

• To evaluate the immunogenicity and efficacy of pneumococcal conjugate vaccines.
• To assess antibody response, avidity, and opsonophagocytic activity in mice immunized with type 9V PS conjugates.
• To investigate intranasal immunization with glycoconjugate vaccines as a potential prevention strategy.

Main Methods:

• Mice were immunized with type 9V PS conjugated to inactivated pneumolysin (Ply) or autolysin (Aly), or with 9V PS alone.
• Serum IgG and IgM concentrations, antibody avidity, and opsonophagocytic activity against 9V pneumococci were measured.
• Intranasal immunization with type 9V conjugate or 9V PS was performed, and antibody production and protection against virulent pneumococci were assessed.

Main Results:

• Conjugate vaccines induced higher and sustained serum IgG and IgM concentrations against 9V PS compared to 9V PS alone.
• Conjugate immunization resulted in high relative avidities of IgG and IgM antibodies and significant opsonophagocytic activity.
• Intranasal immunization with glycoconjugates led to robust IgG and IgA antibody production in various tissues and provided protection against pneumococcal challenge.

Conclusions:

• Pneumococcal conjugate vaccines elicit robust, long-lasting antibody responses and effective functional activity.
• Intranasal administration of glycoconjugate vaccines is a promising and convenient approach for preventing pneumococcal infections.